Allergic Rhinitis Drugs Market Size By Disease (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), By Treatment (Antihistamines, Immunotherapy {SCIT, SLIT}, Corticosteroids, Decongestants), By Drug (Prescription, OTC

Allergic Rhinitis Drugs Market Size By Disease (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), By Treatment (Antihistamines, Immunotherapy {SCIT, SLIT}, Corticosteroids, Decongestants), By Drug (Prescription, OTC), By Route of Administration (Oral, Nasal, Intraocular, Intravenous), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Channel), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2023 - 2032


Allergic Rhinitis Drugs Market is expected to grow significantly during 2023-2032, owing to the increasing rate of respiratory diseases. Air pollution is one of the critical factors contributing to the spread of respiratory infections. According to reports, asthma and chronic obstructive pulmonary disease (COPD) account for most respiratory illnesses in India.

Besides, rising air pollution leads to high levels of allergic pollen and result in a rising number of patients suffering from allergic rhinitis. The constant innovations in monitoring the impact of pollution levels on allergic rhinitis will play a key role in market expansion.

Overall, the allergic rhinitis drugs market is segmented in terms of disease, treatment, drug, route of administration, distribution channel, and region.

Considering the disease, the occupational allergic rhinitis market held over USD 1.2 billion market share in 2022 and is slated to grow exponentially through 2032. The growth can be attributed to the rising cases of occupational allergic rhinitis caused by allergens from hair spray and fumes, strong odors, diesel exhaust, pollutants from factories, and cleaning solutions. Besides, the mounting use of air conditioning and strict regulations imposed by the government regarding factory emissions will support the segmental growth by 2032.

Based on treatment, the corticosteroids segment held over USD 3.6 billion market share in 2022 and is anticipated to register notable gains through 2032. Some key benefits offered by corticosteroids, such as near-instant pain relief, rapid reduction in inflammation, permanent cure, sometimes, in the case of a localized injury, and a high success rate, are expected to propel the product adoption.

On the basis of drug, the OTC segment is depicted to grow considerably through 2032, owing to the availability of several medications for allergic rhinitis treatment on non-prescription or over the counter. The rising trend of self-medication, coupled with the increasing adoption of online platforms for ordering medicines, will play a key role in complementing the segmental expansion.

By route of administration, the nasal segment accounted for over USD 4.6 billion in 2022 and is slated to grow exponentially over the forecast period, owing to the increasing use of nasal sprays as one of the primary medications for treating allergic rhinitis. Besides, nasal sprays relieve inflammation faster, are easy to use, and available as over-the-counter products. All these factors are anticipated to accelerate the product development.

Considering the distribution channel, the retail pharmacy segment held over 33% market share in 2022 and is slated to register healthy growth during the estimated timeframe. Easy accessibility and availability of different medications at affordable price ranges are key factors supporting the segment expansion in the coming years.

Regionally, the Europe allergic rhinitis drugs market accounted for over 30% revenue share in 2022 and is expected to witness significant growth throughout 2032. The rising inclination of consumers towards allergic self-medication trends and high disposable income are some of the key factors that are projected to drive the regional market growth in the ensuing years.